761 related articles for article (PubMed ID: 32108526)
1. Sulforaphane prevents right ventricular injury and reduces pulmonary vascular remodeling in pulmonary arterial hypertension.
Kang Y; Zhang G; Huang EC; Huang J; Cai J; Cai L; Wang S; Keller BB
Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H853-H866. PubMed ID: 32108526
[TBL] [Abstract][Full Text] [Related]
2. Sulforaphane Does Not Protect Right Ventricular Systolic and Diastolic Functions in Nrf2 Knockout Pulmonary Artery Hypertension Mice.
Zhang G; Kang Y; Cathey D; LeBlanc AJ; Cai J; Cai L; Wang S; Huang J; Keller BB
Cardiovasc Drugs Ther; 2022 Jun; 36(3):425-436. PubMed ID: 35157168
[TBL] [Abstract][Full Text] [Related]
3. Direct and indirect protection of right ventricular function by estrogen in an experimental model of pulmonary arterial hypertension.
Liu A; Schreier D; Tian L; Eickhoff JC; Wang Z; Hacker TA; Chesler NC
Am J Physiol Heart Circ Physiol; 2014 Aug; 307(3):H273-83. PubMed ID: 24906919
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane alleviated vascular remodeling in hypoxic pulmonary hypertension via inhibiting inflammation and oxidative stress.
Pan J; Wang R; Pei Y; Wang D; Wu N; Ji Y; Tang Q; Liu L; Cheng K; Liu Q; Sun J; Gong M; Zheng X; Li J; Zhang C; Yuan Y
J Nutr Biochem; 2023 Jan; 111():109182. PubMed ID: 36220525
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary artery banding is a relevant model to study the right ventricular remodeling and dysfunction that occurs in pulmonary arterial hypertension.
Akazawa Y; Okumura K; Ishii R; Slorach C; Hui W; Ide H; Honjo O; Sun M; Kabir G; Connelly K; Friedberg MK
J Appl Physiol (1985); 2020 Aug; 129(2):238-246. PubMed ID: 32644912
[TBL] [Abstract][Full Text] [Related]
6. Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.
da Silva Gonçalves Bós D; Van Der Bruggen CEE; Kurakula K; Sun XQ; Casali KR; Casali AG; Rol N; Szulcek R; Dos Remedios C; Guignabert C; Tu L; Dorfmüller P; Humbert M; Wijnker PJM; Kuster DWD; van der Velden J; Goumans MJ; Bogaard HJ; Vonk-Noordegraaf A; de Man FS; Handoko ML
Circulation; 2018 Feb; 137(9):910-924. PubMed ID: 29167228
[TBL] [Abstract][Full Text] [Related]
7. Macrophage-NLRP3 Activation Promotes Right Ventricle Failure in Pulmonary Arterial Hypertension.
Al-Qazazi R; Lima PDA; Prisco SZ; Potus F; Dasgupta A; Chen KH; Tian L; Bentley RET; Mewburn J; Martin AY; Wu D; Jones O; Maurice DH; Bonnet S; Provencher S; Prins KW; Archer SL
Am J Respir Crit Care Med; 2022 Sep; 206(5):608-624. PubMed ID: 35699679
[No Abstract] [Full Text] [Related]
8. Fischer rats exhibit maladaptive structural and molecular right ventricular remodelling in severe pulmonary hypertension: a genetically prone model for right heart failure.
Suen CM; Chaudhary KR; Deng Y; Jiang B; Stewart DJ
Cardiovasc Res; 2019 Mar; 115(4):788-799. PubMed ID: 30357319
[TBL] [Abstract][Full Text] [Related]
9. Distinct right ventricle remodeling in response to pressure overload in the rat.
Mendes-Ferreira P; Santos-Ribeiro D; Adão R; Maia-Rocha C; Mendes-Ferreira M; Sousa-Mendes C; Leite-Moreira AF; Brás-Silva C
Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H85-95. PubMed ID: 27199115
[TBL] [Abstract][Full Text] [Related]
10. Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model.
Lu M; Chen LY; Gairhe S; Mazer AJ; Anderson SA; Nelson JNH; Noguchi A; Siddique MAH; Dougherty EJ; Zou Y; Johnston KA; Yu ZX; Wang H; Wang S; Sun J; Solomon SB; Vanderpool RR; Solomon MA; Danner RL; Elinoff JM
Am J Physiol Lung Cell Mol Physiol; 2022 Mar; 322(3):L315-L332. PubMed ID: 35043674
[TBL] [Abstract][Full Text] [Related]
11. Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension.
Boehm M; Arnold N; Braithwaite A; Pickworth J; Lu C; Novoyatleva T; Kiely DG; Grimminger F; Ghofrani HA; Weissmann N; Seeger W; Lawrie A; Schermuly RT; Kojonazarov B
BMC Pulm Med; 2018 Mar; 18(1):41. PubMed ID: 29499691
[TBL] [Abstract][Full Text] [Related]
12. Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation.
Bai Y; Chen Q; Sun YP; Wang X; Lv L; Zhang LP; Liu JS; Zhao S; Wang XL
Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28636290
[TBL] [Abstract][Full Text] [Related]
13. Colchicine Depolymerizes Microtubules, Increases Junctophilin-2, and Improves Right Ventricular Function in Experimental Pulmonary Arterial Hypertension.
Prins KW; Tian L; Wu D; Thenappan T; Metzger JM; Archer SL
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28566298
[TBL] [Abstract][Full Text] [Related]
14. Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension.
Sun XQ; Peters EL; Schalij I; Axelsen JB; Andersen S; Kurakula K; Gomez-Puerto MC; Szulcek R; Pan X; da Silva Goncalves Bos D; Schiepers REJ; Andersen A; Goumans MJ; Vonk Noordegraaf A; van der Laarse WJ; de Man FS; Bogaard HJ
Am J Respir Cell Mol Biol; 2021 Mar; 64(3):331-343. PubMed ID: 33264068
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary vascular mechanical consequences of ischemic heart failure and implications for right ventricular function.
Philip JL; Murphy TM; Schreier DA; Stevens S; Tabima DM; Albrecht M; Frump AL; Hacker TA; Lahm T; Chesler NC
Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1167-H1177. PubMed ID: 30767670
[TBL] [Abstract][Full Text] [Related]
16. Sulforaphane enriched transcriptome of lung mitochondrial energy metabolism and provided pulmonary injury protection via Nrf2 in mice.
Cho HY; Miller-DeGraff L; Blankenship-Paris T; Wang X; Bell DA; Lih F; Deterding L; Panduri V; Morgan DL; Yamamoto M; Reddy AJ; Talalay P; Kleeberger SR
Toxicol Appl Pharmacol; 2019 Feb; 364():29-44. PubMed ID: 30529165
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
[TBL] [Abstract][Full Text] [Related]
18. Estradiol improves right ventricular function in rats with severe angioproliferative pulmonary hypertension: effects of endogenous and exogenous sex hormones.
Frump AL; Goss KN; Vayl A; Albrecht M; Fisher A; Tursunova R; Fierst J; Whitson J; Cucci AR; Brown MB; Lahm T
Am J Physiol Lung Cell Mol Physiol; 2015 May; 308(9):L873-90. PubMed ID: 25713318
[TBL] [Abstract][Full Text] [Related]
19. ADAMTS8 Promotes the Development of Pulmonary Arterial Hypertension and Right Ventricular Failure: A Possible Novel Therapeutic Target.
Omura J; Satoh K; Kikuchi N; Satoh T; Kurosawa R; Nogi M; Ohtsuki T; Al-Mamun ME; Siddique MAH; Yaoita N; Sunamura S; Miyata S; Hoshikawa Y; Okada Y; Shimokawa H
Circ Res; 2019 Oct; 125(10):884-906. PubMed ID: 31556812
[TBL] [Abstract][Full Text] [Related]
20. Sildenafil prevents and reverses transverse-tubule remodeling and Ca(2+) handling dysfunction in right ventricle failure induced by pulmonary artery hypertension.
Xie YP; Chen B; Sanders P; Guo A; Li Y; Zimmerman K; Wang LC; Weiss RM; Grumbach IM; Anderson ME; Song LS
Hypertension; 2012 Feb; 59(2):355-62. PubMed ID: 22203744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
